[ CAS No. 1245506-61-9 ] {[proInfo.proName]}

Name: 1245506-61-9|2-Chloro-5-methoxy-4-methylpyrimidine|98%
Brand: Ambeed
SKU: A251406
Rating: 91 (30 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

DV 2D 3D

3d Animation Molecule Structure of 1245506-61-9

Structure of 1245506-61-9 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 1245506-61-9 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 1245506-61-9 ]

SDS Specification

Alternatived Products of [ 1245506-61-9 ]

Product Details of [ 1245506-61-9 ]

CAS No. :	1245506-61-9	MDL No. :	MFCD22394135
Formula :	C₆H₇ClN₂O	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	GBQFWSOESDYTPU-UHFFFAOYSA-N
M.W :	158.59	Pubchem ID :	71306242
Synonyms :

Calculated chemistry of [ 1245506-61-9 ]

Physicochemical Properties

Num. heavy atoms :	10
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.33
Num. rotatable bonds :	1
Num. H-bond acceptors :	3.0
Num. H-bond donors :	0.0
Molar Refractivity :	38.5
TPSA :	35.01 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	Yes
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-6.17 cm/s

Lipophilicity

Log Po/w (iLOGP) :	2.11
Log Po/w (XLOGP3) :	1.54
Log Po/w (WLOGP) :	1.45
Log Po/w (MLOGP) :	0.28
Log Po/w (SILICOS-IT) :	1.95
Consensus Log Po/w :	1.47

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	1.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-2.17
Solubility :	1.07 mg/ml ; 0.00674 mol/l
Class :	Soluble
Log S (Ali) :	-1.88
Solubility :	2.07 mg/ml ; 0.013 mol/l
Class :	Very soluble
Log S (SILICOS-IT) :	-2.77
Solubility :	0.269 mg/ml ; 0.00169 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	1.88

Safety of [ 1245506-61-9 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302-H315-H319-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 1245506-61-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 1245506-61-9 ]
Downstream synthetic route of [ 1245506-61-9 ]

[ 1245506-61-9 ] Synthesis Path-Upstream 1~3

1
[ 75-16-1 ]
[ 19646-07-2 ]
[ 1245506-61-9 ]

Yield	Reaction Conditions	Operation in experiment
54%	With iron(III)-acetylacetonate In 2-methyltetrahydrofuran; 1-methyl-pyrrolidin-2-one at 0℃; for 0.5 h; Inert atmosphere	To a solution of 2,4-dichloro-5-methoxypyrimidine (1 g, 5.59 mmol) in tetrahydrofuran (32.2 mL) / Nmethyl-2-pyrrolidone (2.424 mL) was added ferric acetylacetonate (0.197 g, 0.559 mmol) and themixture was cooled to 0 °C under nitrogen. Then methylmagnesium bromide (2.62 mL, 8.38 mmol,3.2 M in MeTHF) was added dropwise. The mixture was stirred for 30 mm under nitrogen at 0 °C. The reaction was quenched with saturated aqueous NH4CI solution (10 mL) and the mixture allowedwarm to rt. Diethyl ether was added, the layers were separated and the aqueous layer was further extracted with diethyl ether (4 x 15 mL). The combined organic extracts were dried over a hydrophobic frit and concentrated in vacuo to give an orange oil. The crude product was loaded indichloromethane (3 mL) and purified on a silica cartridge (25 g) using a gradient of 0-30percent cyclohexane/AcOEt over 10 CV. The appropriate fractions were combined and the solvent evaporated in vacuo to give the product as a white solid (475 mg, 3.00 mmol, 54percent).LCMS (2 mm Formic): Rt = 0.64 mi [MH] = 159.

Reference： [1] Patent: WO2014/140076, 2014, A1, . Location in patent: Page/Page column 164; 165

2
[ 823-96-1 ]
[ 19646-07-2 ]
[ 1245506-61-9 ]

Reference： [1] Patent: WO2010/103334, 2010, A1, . Location in patent: Page/Page column 21
[2] Patent: WO2011/147951, 2011, A1, . Location in patent: Page/Page column 49

3
[ 676-58-4 ]
[ 19646-07-2 ]
[ 1245506-61-9 ]

Reference： [1] Patent: US2012/95031, 2012, A1, . Location in patent: Page/Page column 28-29

[ 1245506-61-9 ] Synthesis Path-Downstream 1~58

1
[ 823-96-1 ]
[ 19646-07-2 ]
[ 1245506-61-9 ]

Yield	Reaction Conditions	Operation in experiment
32.3%	With potassium phosphate; In tetrahydrofuran; at 65℃; for 16.0h;Sealed tube;	A degassed mixture of 2,4-dichloro-5-methoxypyrimidine (5.70 g, 31.8 mmol), trimethyl-boroxine (5.34 mL, 38.2 mmol) and K3PO4 (13.5 g, 63.7 mmol) in THF (50 mL) was sealed and stirred at 65 C for 16 h, then was cooled to RT. The reaction mixture was partitioned between EtOAc and water. The aqueous phase was extracted with EtOAc (2X); the combined organic extracts were dried (MgS04) and concentrated in vacuo. The crude material was chromatographed (220 g Si02; continuous gradient from 0% to 30% EtOAc in Hexane over 25 min) to give the title compound (1.6 g, 10.28 mmol 32.3%) as a white solid. 1H NMR (500 MHz, CDCI3) d 8.05 (s, 1H), 3.92 (s, 3H), 2.45 (s, 3H).
32.3%	With potassium phosphate; In tetrahydrofuran; at 65℃; for 16.0h;Inert atmosphere;	A degassed mixture of 2,4~dichloro-5-methoxypyrimidine (5.70 g, 31.8 mmol), trimethyl-boroxine (5.34 mL, 38.2 mmol) and K3PO4 (13.52 g, 63.7 mmol) in THF (50 mL) was stirred at 65 C for 16 h, then was cooled to RT. The reaction mixture was partitioned between EtOAc and water. The aqueous phase was extracted with EtOAc (2X); the combined organic extracts were dried (MgS04) and concentrated in vacuo. The crude product was chromatographed (220 g Si02; continuous gradient from 0% to 30% EtOAc in Hexane over 25 min) to give the title compound (1.6 g, 10.3 mmol, 32.3%) as a white solid. NMR (500 MHz, CDCl3) d 8.05 (s, 1H), 3.92 (s, 3H), 2.45 (s, 3H).
	With potassium phosphate;bis-triphenylphosphine-palladium(II) chloride; In tetrahydrofuran; for 16.0h;Reflux;	To a solution of 2,4-dichloro-5-methoxypyrimidine (1.5g, 8.38mmol) in THF (15mL) under argon was added trimethylboroxine (1.2g, 9.22mmol), dichlorobis(triphenylphosphine)- palladium (0.6g, 0.84mmol) and potassium phosphate (3.6g, 16.76mmol) and the mixture was heated to reflux for 16h. The reaction was diluted with EtOAc and washed with water, then dried (Na2SO4). Removal of the solvent in vacuo followed by purification by column chromatography (IH:EtOAc, 100:0, 90:10, 80:20, 70:30) afforded the title compound: RT = 2.45 min; mlz (ES+) = 159.0 [M + H]+.

With potassium phosphate;bis-triphenylphosphine-palladium(II) chloride; In tetrahydrofuran; for 16.0h;Inert atmosphere; Reflux;

To a solution of 2,4-dichloro-5-methoxypyrimidine (1.5g, 8.38mmol) in THF (15mL), under argon, was added trimethylboroxine (1.2g, 9.22mmol),dichlorobis(triphenylphosphine)palladium (0.6g, 0.84mmol) and potassium phosphate (3.6g, 16.76mmol) and the mixture was heated to reflux for 16 h. The reaction was diluted with EtOAc, washed with water, then dried (Na2S04). Removal of the solvent in vacuo and purification by column chromatography (IH:EtOAc, 100:0, 90: 10, 80:20, 70:30) afforded the title compound: RT = 2.45 min; mlz (ES+) = 159.0 [M+ H]+.

Reference： [1]Patent: WO2019/126089,2019,A1 .Location in patent: Page/Page column 98
[2]Patent: WO2019/126103,2019,A1 .Location in patent: Page/Page column 98-99
[3]Patent: WO2010/103334,2010,A1 .Location in patent: Page/Page column 21
[4]Patent: WO2011/147951,2011,A1 .Location in patent: Page/Page column 49

2
[ 1245506-61-9 ]
[ 1245506-62-0 ]

Yield	Reaction Conditions	Operation in experiment
91%	With boron tribromide; In dichloromethane; at -78 - 20℃; for 16.0h;	To a -78 C solution of Intermediate 3B (1.60 g, 10.09 mmol) in DCM (20 mL) was added BBr3 (3.82 mL, 40.4 mmol) dropwise. The reaction mixture was allowed to slowly warm to RT and stirred for 16 h at RT, then was cautiously quenched with satd aq. NaHC03 (pH adjusted to ~4) and partitioned between EtOAc and water. The aqueous phase was extracted with EtOAc (2x); the combined organic layers were dried (MgS04) and concentrated in vacuo. The crude product was chromato graphed (40 g S1O2; continuous gradient from 0-100% EtOAc in Hexane over 15 min) to afford the title compound (1.33 g, 9.20 mmol, 91 % yield) as a white solid. NMR (400 MHz, DMSO- d6) d 10.63 (s, 1H), 8.11 (s, 1H), 2.34 (s, 3H).
91%	With boron tribromide; In dichloromethane; at -78 - 20℃; for 16.0h;	To a -78 C solution of Intermediate 3B (1.60 g, 10.09 mmol) in DCM (20 mL) was added BBr3 (3.82 mL, 40.4 mmol) dropwise. The reaction mixture was allowed to slowly warm to RT and stirred for 16 h at RT, then was cautiously quenched with satd aq. NaHC03 (pH adjusted to ~4) and partitioned between EtOAc and water. The aqueous phase was extracted with EtOAc (2x), and the combined organic layers were dried (MgS04) and concentrated in vacuo. The crude product was chromatographed (40 g S1O2; continuous gradient from 0-100% EtOAc in Hexane over 15 min) to afford the title compound (1.33 g, 9.20 mmol, 91 % yield) as a white solid. NMR (400 MHz, DMSO- d6) d 10.63 (s, 1H), 8.11 (s, 1H), 2.34 (s, 3H).
		To a dry solution of <strong>[1245506-61-9]2-chloro-5-methoxy-4-methylpyrimidine</strong> (Preparation 8, l.lg, 6.94mmol) in DCM (2OmL) under argon, cooled to -78C was added boron tribromide (2.63mL, 27.82mmol), dropwise over 15 min. The reaction was allowed to stir at -78C for 20 min then at r.t. for 16h. The mixture was cooled down to -78C and then quenched by the dropwise addition of MeOH. The reaction was allowed to reach r.t. then NaHCO3 was carefully added to adjust the pH to 5. Organics were extracted into EtOAc, washed with brine and dried (Na2SO4). Removal of the solvent in vacuo followed by trituration with DCM afforded the title compound: RT = 2.13 min; mlz (ES+) = 145.0 [M + H]+.

		A dry solution of <strong>[1245506-61-9]2-chloro-5-methoxy-4-methylpyrimidine</strong> (Preparation 55, l . lg, 6.94mmol) in DCM (20mL), under argon, was cooled to -78C. Boron tribromide (2.63mL, 27.82mmol) was added, dropwise over 15 min, then the reaction was allowed to stir at -78C for 20 min before being stirred at r.t. for a further 16 h. The mixture was cooled down to - 78C and quenched by the dropwise addition of MeOH. The reaction was allowed to reach r.t. then NaHCCb was carefully added to adjust the pH to 5. The mixture was extracted with EtOAc and the organic phase was washed with brine, then dried (Na2S04). Removal of the solvent in vacuo and trituration with DCM afforded the title compound: RT = 2.13 min; mlz (ES+) = 145.0 [Mu+ etagamma
		(2) 2-Chloro-4-methylpyrimidin-5-ol (Prep 1-2)A dichloromethane solution (50 ml) of the compound Prep 1-1 (6.6 g) was added dropwise to a dichloromethane solution (1.0 M: 100 ml) of boron tribromide, and the obtained mixture was then stirred at room temperature for 4 days. Thereafter, methanol was added to the reaction mixture, and a 5 N sodium hydroxide aqueous solution was then added to the reaction solution for neutralization. Liquid separation and extraction were carried out successively using chloroform and ethyl acetate at a pH value of approximately pH 2 to 3. The organic layer was dried over magnesium sulfate, and the solvent was then concentrated under reduced pressure. Diethyl ether was added to the obtained residue to solidify it, and the solidified product was collected by filtration and was then dried, so as to obtain the title compound.1H-NMR (400 MHz, DMSO-d6) delta (ppm): 2.32 (s, 3H), 8.09 (s, 1H), 10.61 (s, 1H).

Reference： [1]Patent: WO2019/126089,2019,A1 .Location in patent: Page/Page column 98
[2]Patent: WO2019/126103,2019,A1 .Location in patent: Page/Page column 99
[3]Patent: WO2010/103334,2010,A1 .Location in patent: Page/Page column 21
[4]Patent: WO2011/147951,2011,A1 .Location in patent: Page/Page column 49
[5]Patent: US2012/95031,2012,A1 .Location in patent: Page/Page column 29

3
[ 1245506-61-9 ]
[ 1351341-62-2 ]

Reference： [1]Patent: WO2011/147951,2011,A1

4
[ 1245506-61-9 ]
[ 1351338-57-2 ]

Reference： [1]Patent: WO2011/147951,2011,A1

5
[ 1245506-61-9 ]
[ 1351345-54-4 ]

Reference： [1]Patent: WO2011/147951,2011,A1

6
[ 1245506-61-9 ]
[ 1351338-59-4 ]

Reference： [1]Patent: WO2011/147951,2011,A1

7
[ 1245506-61-9 ]
[ 1351345-55-5 ]

Reference： [1]Patent: WO2011/147951,2011,A1

8
[ 676-58-4 ]
[ 19646-07-2 ]
[ 1245506-61-9 ]

Yield	Reaction Conditions	Operation in experiment
	iron(III)-acetylacetonate; In tetrahydrofuran; at 10 - 35℃;	Production Example 1Synthesis of 2-methoxy-4-methylpyrimidin-5-ol (Prep 1-5)(1) 2-Chloro-5-methoxy-4-methylpyrimidine (Prep 1-1)2,4-Dichloro-5-methoxypyrimidine (10 g) was dissolved in THF (100 ml), and while cooling, iron(III) acetylacetone (1.97 g), methyl magnesium chloride (3.0 M: 22.4 ml) were then added to the solution. The obtained mixture was stirred at room temperature overnight. Thereafter, iron(III) acetylacetone (1.97 g), and methyl magnesium chloride (3.0 M: 22.4 ml) were added to the reaction solution further twice. Thereafter, a 1 N hydrochloric acid aqueous solution was added to the reaction mixture, and diethyl ether was then added to the reaction solution to carry out liquid separation and extraction. The organic layer was dried over magnesium sulfate, and the solvent was then concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (n-heptane:ethyl acetate), so as to obtain the title compound (6.6 g).1H-NMR (400 MHz, CDCl3) 5 (ppm): 2.46 (s, 3H), 3.92 (s, 3H), 8.06 (s, 1H).

Reference： [1]Patent: US2012/95031,2012,A1 .Location in patent: Page/Page column 28-29

9
[ 1245506-61-9 ]
[ 1369766-62-0 ]

Reference： [1]Patent: US2012/95031,2012,A1

10
[ 1245506-61-9 ]
[ 1369766-60-8 ]

Reference： [1]Patent: US2012/95031,2012,A1

11
[ 1245506-61-9 ]
[ 1369766-61-9 ]

Reference： [1]Patent: US2012/95031,2012,A1

12
[ 1245506-61-9 ]
[ 1369766-65-3 ]

Reference： [1]Patent: US2012/95031,2012,A1

13
[ 1245506-61-9 ]
[ 1369766-63-1 ]

Reference： [1]Patent: US2012/95031,2012,A1

14
[ 1245506-61-9 ]
[ 1369768-93-3 ]

Reference： [1]Patent: US2012/95031,2012,A1

15
[ 1245506-61-9 ]
[ 1369768-94-4 ]

Reference： [1]Patent: US2012/95031,2012,A1

16
[ 1245506-61-9 ]
[ 1369768-95-5 ]

Reference： [1]Patent: US2012/95031,2012,A1

17
[ 1245506-61-9 ]
C₁₈H₁₈ClFN₂O₃ [ No CAS ]

Reference： [1]Patent: US2012/95031,2012,A1

18
[ 1245506-61-9 ]
[ 1454928-76-7 ]

Yield	Reaction Conditions	Operation in experiment
	With N-Bromosuccinimide; 2,2'-azobis(isobutyronitrile); In dichloromethane; for 42.0h;Reflux;	General procedure: To a solution of 2-methoxy-5-methylpyridin-3-yl acetate (5.80 g, 32.0 mmol) in anhydrous CH2Cl2 (50 mL) was added with N-bromosuccinimide (5.69 g, 32.0 mmol) and AIBN (530 mg, 3.23 mmol). The reaction mixture was heated at reflux for 24 h, added with N-bromosuccinimide (1.14 g, 6.41 mmol), further heated at reflux for 18 h, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, hexane ramping to CH2Cl2:hexane = 1:1) to give 9 as a colourless liquid (3.88 g, 47%).

Reference： [1]Patent: WO2013/134562,2013,A1 .Location in patent: Paragraph 00386
[2]Bioorganic and Medicinal Chemistry Letters,2016,vol. 26,p. 5674 - 5678
[3]Patent: WO2017/132538,2017,A1 .Location in patent: Page/Page column 153

19
[ 1245506-61-9 ]
[ 1454928-77-8 ]

Reference： [1]Patent: WO2013/134562,2013,A1

20
[ 75-16-1 ]
[ 19646-07-2 ]
[ 1245506-61-9 ]

Yield	Reaction Conditions	Operation in experiment
54%	With iron(III)-acetylacetonate; In 2-methyltetrahydrofuran; 1-methyl-pyrrolidin-2-one; at 0℃; for 0.5h;Inert atmosphere;	To a solution of 2,4-dichloro-5-methoxypyrimidine (1 g, 5.59 mmol) in tetrahydrofuran (32.2 mL) / Nmethyl-2-pyrrolidone (2.424 mL) was added ferric acetylacetonate (0.197 g, 0.559 mmol) and themixture was cooled to 0 C under nitrogen. Then methylmagnesium bromide (2.62 mL, 8.38 mmol,3.2 M in MeTHF) was added dropwise. The mixture was stirred for 30 mm under nitrogen at 0 C. The reaction was quenched with saturated aqueous NH4CI solution (10 mL) and the mixture allowedwarm to rt. Diethyl ether was added, the layers were separated and the aqueous layer was further extracted with diethyl ether (4 x 15 mL). The combined organic extracts were dried over a hydrophobic frit and concentrated in vacuo to give an orange oil. The crude product was loaded indichloromethane (3 mL) and purified on a silica cartridge (25 g) using a gradient of 0-30% cyclohexane/AcOEt over 10 CV. The appropriate fractions were combined and the solvent evaporated in vacuo to give the product as a white solid (475 mg, 3.00 mmol, 54%).LCMS (2 mm Formic): Rt = 0.64 mi [MH] = 159.

Reference： [1]Patent: WO2014/140076,2014,A1 .Location in patent: Page/Page column 164; 165

21
[ 1245506-61-9 ]
C₉H₁₁ClN₂O₃S [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2016,vol. 26,p. 5674 - 5678

22
[ 1245506-61-9 ]
C₉H₁₁ClN₂O₅S [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2016,vol. 26,p. 5674 - 5678

23
[ 1245506-61-9 ]
2-(((2-chloro-5-methoxypyrimidin-4-yl)methyl)sulfonyl)acetic acid [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2016,vol. 26,p. 5674 - 5678

24
[ 1245506-61-9 ]
(E)-2-chloro-5-methoxy-4-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)pyrimidine [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2016,vol. 26,p. 5674 - 5678

25
[ 1245506-61-9 ]
(E)-5-methoxy-4-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)pyrimidin-2-amine [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2016,vol. 26,p. 5674 - 5678

26
[ 1245506-61-9 ]
(E)-5-methoxy-N-methyl-4-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)pyrimidin-2-amine [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2016,vol. 26,p. 5674 - 5678

27
[ 1245506-61-9 ]
C₆H₅ClN₂O₃ [ No CAS ]

Reference： [1]Patent: WO2017/132538,2017,A1

28
[ 1245506-61-9 ]
C₇H₇ClN₂O₂ [ No CAS ]

Reference： [1]Patent: WO2017/132538,2017,A1

29
[ 1245506-61-9 ]
C₆H₅ClN₂O₂ [ No CAS ]

Reference： [1]Patent: WO2017/132538,2017,A1

30
[ 1245506-61-9 ]
2-bromo-4-methylpyrimidin-5-ol [ No CAS ]

Reference： [1]Patent: WO2019/126089,2019,A1
[2]Patent: WO2019/126103,2019,A1

31
[ 1245506-61-9 ]
4-methyl-2-(1-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-1H- pyrazol-4-yl)pyrimidin-5-ol [ No CAS ]

Reference： [1]Patent: WO2019/126089,2019,A1
[2]Patent: WO2019/126103,2019,A1

32
[ 1245506-61-9 ]
C₂₇H₃₇N₇O₄ [ No CAS ]

Reference： [1]Patent: WO2019/126089,2019,A1

33
[ 1245506-61-9 ]
C₂₆H₃₅N₇O₄ [ No CAS ]

Reference： [1]Patent: WO2019/126089,2019,A1

34
[ 1245506-61-9 ]
isopropyl (1S,3S)-3-((4-methyl-2-(1-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-1H-pyrazol-4-yl)pyrimidin-5-yl)oxy)cyclohexane-1-carboxylate [ No CAS ]

Reference： [1]Patent: WO2019/126089,2019,A1
[2]Patent: WO2019/126103,2019,A1
[3]Patent: WO2019/126103,2019,A1

35
[ 1245506-61-9 ]
C₂₆H₃₅N₇O₄ [ No CAS ]

Reference： [1]Patent: WO2019/126089,2019,A1

36
[ 1245506-61-9 ]
isopropyl (1S,3S)-3-((2-(5-(hydroxymethyl)-1-methyl-1H-pyrazol-4-yl)-4-methylpyrimidin-5-yl)oxy)cyclohexane-1-carboxylate [ No CAS ]

Reference： [1]Patent: WO2019/126089,2019,A1
[2]Patent: WO2019/126103,2019,A1
[3]Patent: WO2019/126103,2019,A1

37
[ 1245506-61-9 ]
isopropyl (1S,3S)-3-((2-(5-(bromomethyl)-1-methyl-1H-pyrazol-4-yl)-4-methylpyrimidin-5-yl)oxy)cyclohexane-1-carboxylate [ No CAS ]

Reference： [1]Patent: WO2019/126089,2019,A1
[2]Patent: WO2019/126103,2019,A1
[3]Patent: WO2019/126103,2019,A1

38
[ 1245506-61-9 ]
isopropyl (1S,3S)-3-((2-(5-(azidomethyl)-1-methyl-1H-pyrazol-4-yl)-4-methylpyrimidin-5-yl)oxy)cyclohexane-1-carboxylate [ No CAS ]

Reference： [1]Patent: WO2019/126089,2019,A1
[2]Patent: WO2019/126103,2019,A1
[3]Patent: WO2019/126103,2019,A1

39
[ 1245506-61-9 ]
isopropyl (1S,3S)-3-((2-(5-(aminomethyl)-1-methyl-1H-pyrazol-4-yl)-4-methylpyrimidin-5-yl)oxy)cyclohexane-1-carboxylate [ No CAS ]

Reference： [1]Patent: WO2019/126089,2019,A1
[2]Patent: WO2019/126103,2019,A1
[3]Patent: WO2019/126103,2019,A1

40
[ 1245506-61-9 ]
isopropyl (1S,3S)-3-((2-chloro-4-methylpyrimidin-5-yl)oxy)cyclohexane-1-carboxylate [ No CAS ]

Reference： [1]Patent: WO2019/126089,2019,A1
[2]Patent: WO2019/126103,2019,A1

41
[ 1245506-61-9 ]
isopropyl (1S,3S)-3-((2-(5-formyl-1-methyl-1H-pyrazol-4-yl)-4- methylpyrimidin-5-yl)oxy)cyclohexane-1-carboxylate [ No CAS ]

Reference： [1]Patent: WO2019/126089,2019,A1
[2]Patent: WO2019/126103,2019,A1

42
[ 1245506-61-9 ]
(1S,3S)-3-((2-(5-(((4-isopropoxypyrimidin-2-yl)amino)methyl)-1-methyl-1H-pyrazol-4-yl)-4-methylpyrimidin-5-yl)oxy)cyclohexane-1-carboxylic acid [ No CAS ]

Reference： [1]Patent: WO2019/126089,2019,A1

43
[ 1245506-61-9 ]
(1S,3S)-3-((2-(5-(((4-ethoxypyrimidin-2-yl)amino)methyl)-1-methyl-1H-pyrazol-4-yl)-4-methyl-pyrimidin-5-yl)oxy)cyclohexane-1-carboxylic acid bis(trifluoroacetic acid) [ No CAS ]

Reference： [1]Patent: WO2019/126089,2019,A1

44
[ 1245506-61-9 ]
isopropyl (1S,3S)-3-((2-bromo-4-methylpyrimidin-5-yl)oxy)cyclohexane-1-carboxylate [ No CAS ]

Reference： [1]Patent: WO2019/126089,2019,A1
[2]Patent: WO2019/126103,2019,A1

45
[ 1245506-61-9 ]
tert-butyl 4-(5-(((1S,3S)-3-(isopropoxycarbonyl)cyclohexyl)oxy)-4-methylpyrimidin-2-yl)-1-methyl-1H-pyrazole-5-carboxylate [ No CAS ]

Reference： [1]Patent: WO2019/126089,2019,A1
[2]Patent: WO2019/126103,2019,A1

46
[ 1245506-61-9 ]
4-(5-(((1S,3S)-3-(isopropoxycarbonyl)cyclohexyl)oxy)-4-methylpyrimidin-2-yl)-1-methyl-1H-pyrazole-5-carboxylic acid [ No CAS ]

Reference： [1]Patent: WO2019/126089,2019,A1
[2]Patent: WO2019/126103,2019,A1

47
[ 1245506-61-9 ]
isopropyl (1S,3S)-3-((2-(5-((tert-butoxycarbonyl)amino)-1-methyl-1H-pyrazol-4-yl)-4-methylpyrimidin-5-yl)oxy)cyclohexane-1-carboxylate [ No CAS ]

Reference： [1]Patent: WO2019/126089,2019,A1
[2]Patent: WO2019/126103,2019,A1

48
[ 1245506-61-9 ]
isopropyl (1S,3S)-3-((2-(5-amino-1-methyl-1H-pyrazol-4-yl)-4-methylpyrimidin-5-yl)oxy)cyclohexane-1-carboxylate TFA salt [ No CAS ]

Reference： [1]Patent: WO2019/126089,2019,A1
[2]Patent: WO2019/126103,2019,A1

49
[ 1245506-61-9 ]
(1S,3S)-3-((2-(5-((4-isopropoxypyrimidin-2-yl)amino)-1-methyl-1H-pyrazol-4-yl)-4-methyl-pyrimidin-5-yl)oxy)cyclohexane-1-carboxylic acid bis(trifluoroacetic acid) [ No CAS ]

Reference： [1]Patent: WO2019/126089,2019,A1

50
[ 1245506-61-9 ]
isopropyl (1S,3S)-3-((2-(5-(((4-chloro-6-isopropyl-1,3,5-triazin-2-yl)amino)methyl)-1-methyl-1H-pyrazol-4-yl)-4-methylpyrimidin-5-yl)oxy)cyclohexane-1-carboxylate [ No CAS ]

Reference： [1]Patent: WO2019/126089,2019,A1

51
[ 1245506-61-9 ]
isopropyl (1S,3S)-3-((2-(5-(((4-isopropyl-1,3,5-triazin-2-yl)amino)methyl)-1-methyl-1H-pyrazol-4-yl)-4-methylpyrimidin-5-yl)oxy)cyclohexane-1-carboxylate [ No CAS ]

Reference： [1]Patent: WO2019/126089,2019,A1

52
[ 1245506-61-9 ]
(1S,3S)-3-((2-(5-(((4-isopropyl-1,3,5-triazin-2-yl)amino)methyl)-1-methyl-1H-pyrazol-4-yl)-4-methylpyrimidin-5-yl)oxy)cyclohexane-1-carboxylic acid [ No CAS ]

Reference： [1]Patent: WO2019/126089,2019,A1

53
[ 1245506-61-9 ]
(1S,3S)-3-((4-methyl-2-(1-methyl-5-((3-propyl-1,2,4-thiadiazol-5-yl)amino)-1H-pyrazol-4-yl)pyrimidin-5-yl)oxy)cyclohexane-1-carboxylic acid [ No CAS ]

Reference： [1]Patent: WO2019/126103,2019,A1

54
[ 1245506-61-9 ]
C₂₇H₃₉N₇O₄*2C₂HF₃O₂ [ No CAS ]

Reference： [1]Patent: WO2019/126103,2019,A1

55
[ 1245506-61-9 ]
C₂₄H₃₃N₇O₄*2C₂HF₃O₂ [ No CAS ]

Reference： [1]Patent: WO2019/126103,2019,A1

56
[ 1245506-61-9 ]
(1S,3S)-3-((2-(5-((4-(cyclopropylmethyl)-1H-1,2,3-triazol-1-yl)methyl)-1-methyl-1H-pyrazol-4-yl)-4-methylpyrimidin-5-yl)oxy)cyclohexane-1-carboxylic acid [ No CAS ]

Reference： [1]Patent: WO2019/126103,2019,A1
[2]Patent: WO2019/126103,2019,A1

57
[ 1245506-61-9 ]
C₂₅H₂₈N₈O₃*2C₂HF₃O₂ [ No CAS ]

Reference： [1]Patent: WO2019/126103,2019,A1

58
[ 1245506-61-9 ]
(1S,3S)-3-((2-(5-(((3-isopropyl-1,2,4-thiadiazol-5-yl)amino)methyl)-1-methyl-1H-pyrazol-4-yl)-4-methylpyrimidin-5-yl)oxy)cyclohexane-1-carboxylic acid [ No CAS ]

Reference： [1]Patent: WO2019/126103,2019,A1
[2]Patent: WO2019/126103,2019,A1

Same Skeleton Products

Related Products

Historical Records

Related Functional Groups of
[ 1245506-61-9 ]

Chlorides

[ 1289387-30-9 ]

2-Chloro-4-(methoxymethyl)pyrimidine

Similarity: 0.86

[ 22536-65-8 ]

2-Chloro-5-methoxypyrimidine

Similarity: 0.84

[ 169677-66-1 ]

2-Chloro-5-(cyclopropylmethoxy)pyrimidine

Similarity: 0.81

[ 4983-28-2 ]

2-Chloro-5-hydroxypyrimidine

Similarity: 0.79

[ 138274-14-3 ]

5-(Benzyloxy)-2-chloropyrimidine

Similarity: 0.73

Ethers

[ 1289387-30-9 ]

2-Chloro-4-(methoxymethyl)pyrimidine

Similarity: 0.86

[ 22536-65-8 ]

2-Chloro-5-methoxypyrimidine

Similarity: 0.84

[ 169677-66-1 ]

2-Chloro-5-(cyclopropylmethoxy)pyrimidine

Similarity: 0.81

[ 114969-64-1 ]

5-Methoxypyrimidine-4-carbonitrile

Similarity: 0.75

[ 138274-14-3 ]

5-(Benzyloxy)-2-chloropyrimidine

Similarity: 0.73

Related Parent Nucleus of
[ 1245506-61-9 ]

Pyrimidines

[ 1289387-30-9 ]

2-Chloro-4-(methoxymethyl)pyrimidine

Similarity: 0.86

[ 22536-65-8 ]

2-Chloro-5-methoxypyrimidine

Similarity: 0.84

[ 169677-66-1 ]

2-Chloro-5-(cyclopropylmethoxy)pyrimidine

Similarity: 0.81

[ 4983-28-2 ]

2-Chloro-5-hydroxypyrimidine

Similarity: 0.79

[ 114969-64-1 ]

5-Methoxypyrimidine-4-carbonitrile

Similarity: 0.75

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 1245506-61-9 ] {[proInfo.proName]}

Quality Control of [ 1245506-61-9 ]

Related Doc. of [ 1245506-61-9 ]

Product Details of [ 1245506-61-9 ]

Calculated chemistry of [ 1245506-61-9 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 1245506-61-9 ]

Application In Synthesis of [ 1245506-61-9 ]

[ 1245506-61-9 ] Synthesis Path-Upstream 1~3

[ 1245506-61-9 ] Synthesis Path-Downstream 1~58

Related Functional Groups of [ 1245506-61-9 ]

Chlorides

Ethers

Related Parent Nucleus of [ 1245506-61-9 ]

Pyrimidines

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 1245506-61-9 ]

Related Parent Nucleus of
[ 1245506-61-9 ]